Yunnan Baiyao and Other Pharma Companies Receive Institutional Research Visits; Innovative Drug Development Remains a Key Focus

　　【Pharmaceutical Network - Industry Dynamics] In early June, the pharmaceutical industry saw a surge in institutional research activities, with multiple pharmaceutical companies, including Yunnan Baiyao, Front Pharmaceutical, and Northland, receiving visits from institutional investors. Meanwhile, innovative drug development remains a key focus for these institutions.
 

On June 4, Yunnan Baiyao saw adjustments in holdings by multiple institutional investors. In response to institutional inquiries regarding the progress of innovative drug R&D, the company stated that for its INR101 diagnostic radiopharmaceutical project, clinical Phase III trials have been initiated at 29 out of 32 research centers, with 239 subjects enrolled. For its INR102 therapeutic radiopharmaceutical project, three subjects in the low-dose group and one subject in the medium-dose group of the Phase I/IIa clinical trial have been enrolled and administered the drug; additionally, two subjects completed screening for INR101. Recently, the INB301 monoclonal antibody project for the treatment of cancer cachexia obtained permission from the U.S. FDA to conduct clinical trials. Previously, the Investigational New Drug (IND) application for INB301 injection was officially accepted by the National Medical Products Administration on February 24, 2026, included in the 30-day fast-track review and approval process for innovative drugs, and received clinical trial approval on March 30, 2026.
 

In response to institutional investors’ inquiries regarding the progress of its innovative drug pipeline, Beijing Front Pharmaceutical Co., Ltd. stated that, as of now, the Phase I clinical trial of FY101 injection, an intrahepatic delivery project, is proceeding as planned. The observed efficacy results have met the company’s expectations, and upon successful completion, the Phase II clinical trial will be initiated as scheduled. Meanwhile, the Phase I clinical trial of FY103 injection is advancing in an orderly manner according to plan.
 

Furthermore, in response to questions regarding centralized procurement, Beijing Front Pharmaceutical Co., Ltd. stated that since the implementation of the national volume-based procurement (VBP) policy, a total of 23 of its product varieties have been successfully awarded bids in national VBP programs. In the 11th round of centralized procurement, six of the company’s products were selected, four of which had not previously generated sales in the domestic market. The company will continue to closely monitor and actively respond to national policies on centralized procurement, while making thorough preparations for bidding in the 12th round and implementing post-procurement market strategies.
 

Northland stated during an institutional survey that in May 2026, the National Medical Products Administration (NMPA) approved the market launch of its Cedomingji Injection (brand name: Huasuoling) for the treatment of limb ulcers caused by severe lower extremity ischemia (such as arteriosclerosis obliterans of the lower extremities, thromboangiitis obliterans, and diabetic lower extremity ischemia) in patients who are not suitable for revascularization surgery or where surgical outcomes are poor. Cedomingji Injection (brand name: Huasuoling) is an angiogenesis-promoting therapeutic drug approved in China, and it is currently the only approved plasmid-based gene therapy drug. Regarding the pricing of Cedomingji Injection, Northland indicated that the pricing of new drugs requires comprehensive consideration of multiple factors, including pharmacoeconomic evaluations, market research, and comparisons with the prices of existing treatments for clinical indications. Currently, the company has not determined the price, and specific pricing remains subject to further study and determination.
 

According to research disclosures from multiple pharmaceutical companies, these enterprises are accelerating their transformation toward frontier sectors such as innovative drugs, high-end formulations, gene therapy, and radiopharmaceuticals. Simultaneously, they are actively adapting to centralized procurement policies, achieving a dual track of innovative breakthroughs and stable operations. As R&D pipelines continue to advance and innovative achievements are increasingly commercialized, the high-quality development momentum of China’s pharmaceutical industry will be further consolidated.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice for any person.